scholarly journals " Hybrid therapy as first-line regimen for Helicobacter pylori eradication in a high clarithromycin resistance area: a prospective open-label trial"

2017 ◽  
Author(s):  
Sotirios D. Georgopoulos
Keyword(s):  
Helicobacter Pylori ◽  
First Line ◽  
Open Label ◽  
Hybrid Therapy ◽  
Helicobacter Pylori Eradication ◽  
Clarithromycin Resistance ◽  
Open Label Trial

scholarly journals Sa1910 Time Trends for Helicobacter pylori Eradication Rate of the First-Line and Second-Line Japanese Regimens and Clarithromycin Resistance

2013 ◽  
Vol 144 (5) ◽  
pp. S-332 ◽  
Author(s):  
Naoko Tsuji ◽  
Naoki Okumura ◽  
Satoko Taniike ◽  
Takehisa Takaba ◽  
Nozomu Matsumoto ◽  
...  
Keyword(s):  
Helicobacter Pylori ◽  
Time Trends ◽  
Eradication Rate ◽  
Second Line ◽  
First Line ◽  
Helicobacter Pylori Eradication ◽  
Clarithromycin Resistance

scholarly journals Pharmacoeconomic analysis of classic and alternative eradication therapy regimens for Helicobacter pylori

2019 ◽  
pp. 148-151
Author(s):  
A. M. Veliyev ◽  
D. N. Andreyev ◽  
E. V. Partsvania-Vinogradova
Keyword(s):  
Helicobacter Pylori ◽  
Pharmacoeconomic Analysis ◽  
Eradication Therapy ◽  
Sequential Therapy ◽  
Point Of View ◽  
First Line ◽  
Hybrid Therapy ◽  
Economic Point ◽  
Helicobacter Pylori Eradication ◽  
Economic Balance

The article presents the results of pharmacoeconomic analysis of classical and alternative schemes of the first line of Helicobacter pylori eradication therapy used in Russian practice. The most profitable from the economic point of view were sequential therapy, quadrotherapy with bismuth drug and hybrid therapy. In turn, from the point of view of clinical and economic balance, such schemes as triple therapy with addition of bismuth drug, as well as quadrotherapy without bismuth drug were the most optimal.

scholarly journals N-acetyl cysteine as an adjunct to standard anti-Helicobacter pylori eradication regimen in patients with dyspepsia: A prospective randomized, open-label trial

2014 ◽  
Vol 3 (1) ◽  
pp. 189 ◽  
Author(s):  
Mehdi Zobeiri ◽  
Hojatolah Rahimi ◽  
Jalal Hashemi ◽  
Fariba Arjomandi ◽  
Hamed Daghagzadeh ◽  
...  
Keyword(s):  
Helicobacter Pylori ◽  
Open Label ◽  
Helicobacter Pylori Eradication ◽  
Open Label Trial ◽  
Acetyl Cysteine

scholarly journals Randomised clinical trial comparing concomitant and hybrid therapy for eradication of Helicobacter pylori infection

PLoS ONE ◽  
2020 ◽  
Vol 15 (12) ◽  
pp. e0244500
Author(s):  
Antonio Mestrovic ◽  
Nikola Perkovic ◽  
Josko Bozic ◽  
Mirela Pavicic Ivelja ◽  
Jonatan Vukovic ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Helicobacter Pylori ◽  
Adverse Events ◽  
Therapy Group ◽  
Compliance Rate ◽  
Randomised Clinical Trial ◽  
First Line ◽  
Open Label ◽  
Hybrid Therapy ◽  
Significant Difference

Background The primary objective of this study was to compare concomitant and hybrid therapy in the first line eradication treatment of Helicobacter pylori infection in Split-Dalmatia County, Croatia, in which clarithromycin resistance is above 20%. The secondary objective of the study was to determine and compare compliance and adverse events rate between these therapeutic protocols. Materials and methods In an open-label, randomised clinical trial 140 patients total with H. pylori infection were randomly assigned to either concomitant (esomeprazole 40 mg, amoxicillin 1 g, metronidazole 500 mg, clarithromycin 500 mg, twice daily for 14 days) or hybrid (esomeprazole 40 mg and amoxicillin 1 g twice daily during 14 days with adding metronidazole 500 mg and clarithromycin 500 mg twice daily, in the last 7 days,) treatment group. Results Eradication rates for concomitant group and hybrid therapy group were 84.1% (58/69) and 83.1% (59/71) respectively in the intention-to-treat analysis and 96.7% (58/60) and 95.2% (59/62) in per-protocol analysis. There was no significant difference between the groups (ITT analysis: P = 0.878; PP analysis: P = 0.675). Adverse events were more frequent in the concomitant group (33.3% vs 18.3%, P = 0.043). There was no difference among groups regarding compliance rate. Conclusion Hybrid therapy has similar eradication rate as concomitant therapy, with lower adverse events rate. In the era of increasing antibiotic resistance, eradication regime with less antibiotic’s usage, as hybrid therapy, should be reasonable first line treatment choice for H. pylori infection. Clinical Trials, gov: NCT03572777.

scholarly journals Ten-day bismuth-containing quadruple therapy versus 7-day proton pump inhibitor-clarithromycin containing triple therapy as first-line empirical therapy for the Helicobacter pylori infection in Korea: a randomized open-label trial

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Young-Il Kim ◽  
Jong Yeul Lee ◽  
Chan Gyoo Kim ◽  
Boram Park ◽  
Jin Young Park ◽  
...  
Keyword(s):  
Helicobacter Pylori ◽  
Line Treatment ◽  
First Line ◽  
Open Label ◽  
Quadruple Therapy ◽  
Intention To Treat ◽  
Open Label Trial ◽  
H Pylori ◽  
Treat Analysis ◽  
First Line Treatment

Abstract Background This randomized, open-label trial aimed to compare the efficacy of 10-day bismuth-containing quadruple therapy (BQT) with 7-day proton-pump inhibitor-clarithromycin containing standard triple therapy (STT) as an empirical first-line Helicobacter pylori therapy. Methods Participants with H. pylori infection were randomly assigned to either 10-day BQT (daily doses of bismuth 300 mg, four times; lansoprazole 30 mg, twice; metronidazole 500 mg, three times; and tetracycline 500 mg, four times) or 7-day STT (lansoprazole 30 mg; amoxicillin 1,000 mg; and clarithromycin 500 mg; each given twice daily). Participants who failed initial therapy were crossed over to the alternative treatment regimen. Primary outcome was the eradication rates of first-line treatment by intention-to-treat analysis. Results Study participants (n = 352) were randomized to receive either 10-day BQT (n = 175) or 7-day STT (n = 177). The BQT-group achieved a significantly higher eradication rate than the STT-group in the intention-to-treat analysis (74.3% vs 57.1%, respectively; P = 0.001), modified intention-to-analysis (87.2% [130/149] vs 68.7% [101/147], respectively; P < 0.001) and per-protocol analysis (92.9% [105/113] vs 70.1% [94/134], respectively; P < 0.001). Although there was no serious adverse event, the compliance was lower with BQT than STT as a higher proportion of participants in the BQT-group discontinued therapy because of adverse events than those in the STT-group (23.1% vs 9.1%, respectively; P = 0.001) Conclusions Ten-day BQT had higher eradication rates compared to that of the 7-day STT as an empirical first-line treatment for H. pylori eradication in Korea. Trial registration: ClinicalTrials.gov, NCT02557932. Registered 23 September 2015, https://clinicaltrials.gov/ct2/show/NCT02557932?term=NCT02557932&draw=2&rank=1.

EFFICACY OF MODIFIED BISMUTH QUADRUPLE THERAPY (RBMA) AS FIRST-LINE THERAPY FOR ERADICATION OF HELICOBACTER PYLORI IN PATIENTS WITH CHRONIC GASTRITIS

2019 ◽  
pp. 28-32
Author(s):  
Van Huy Tran
Keyword(s):  
Helicobacter Pylori ◽  
Adverse Effects ◽  
Chronic Gastritis ◽  
Eradication Rate ◽  
High Rate ◽  
First Line ◽  
Helicobacter Pylori Eradication ◽  
Quadruple Therapy ◽  
First Line Therapy ◽  
Line Therapy

Background and aims: Efficacy with substitution of tetracycline with amoxicillin, an antibiotics having a very low resistance rate and a high tolerability, in bismuth quadruple therapy (BQT) have not been studied in Vietnam. Our study aimed to evaluate the efficacy and tolerability of modified BQT vs. standard BQT for first-line Helicobacter pylori eradication. Patients and methods: This is a randomized, prospective study. 120 patients with H.pylori positive-chronic gastritis were randomly divided into two groups. The RBMA group containing rabeprazole 20 mg, bismuth subsalicylic 524mg, metronidazole 500mg, amoxicillin 1000mg, all 2 times a day, for 14 days. The RBMT group received rabeprazole, bismuth subsalicylic, metronidazole and tetracycline. Evaluation for compliance and drug-related side effects were evaluated at the end of two weeks. 4-6 weeks after the end of treatment, the H.pylori eradication rate was determined by the C13urease breath test. Results: Eradication rate was not statistically significative different between the RBMA and the RBMT: 91.2%; 95% confidence interval, 78.2% - 96.7%) vs. 90%; 95% CI, 81.6% - 96.3%) by per-protocol analysis (p = 0.42) and 86.7% (95%CI, 75.84% - 93.09%) vs. 75% (95%CI, 62.1% - 85.3%) by intention-to-treat analysis (ITT, p = 0.06). Adverse effects were significant higher in the RBMT group than in the RBMA group (48.3% vs. 26.7%; p = 0.071) and rate of good compliance was significantly higher in RBMA group than in RBMT group (p < 0.05). Conclusion: The modified BQT including rabeprazole, bismuth, metronidazole and amoxicillin achieved a fairly high rate of H.pylori infection eradication with a higher compliance and lower rate of adverse effects compared to the BQT in patients with chronic gastritis. Further studies need to conduct to confirm this new regimens as a first-line therapy in our country. Key words: Modified bismuth quadruple therapy, BQT, Helicobacter pylori eradication

Sign in / Sign up

Export Citation Format

Share Document